CCR4 antagonist mogamulizumab decreases Treg immunosuppressive activity [243]; combination of mogamulizumab with anti-PD-1 antibody depletes Treg and increases CD8+ tumor infiltration [244]. This evidence concerns the gene PDCD1 and neoplasm.